Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/54515
Title: | Nationwide COVID-19-EII Study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA registry |
Authors: | |
Filiation: | Servicio de Digestivo. Hospital Universitario de Fuenlabrada |
Keywords: | |
Mesh: | |
Decs: | Enfermedades Inflamatorias del Intestino Infecciones por Coronavirus |
Issue Date: | 14-Jan-2022 |
Citation: | Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra Marina I, et al. Nationwide COVID-19-EII Study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA registry. J Clin Med. 2022;11(2):421. |
Abstract: | We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD. |
PMID: | 35054116 |
URI: | https://hdl.handle.net/20.500.12530/54515 |
Rights: | info:eu-repo/semantics/openAccess |
Appears in Collections: | Hospitales > H. U. de Fuenlabrada > Artículos |
This item is licensed under a Creative Commons License